home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

14.26 +0.77 (+5.71%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

20 21 Next >

2 Stocks Down 30% to Buy Right Now ↗

April 14, 2024

These stocks have plenty of catalysts ahead.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week. ↗

April 12, 2024

These two stocks could be ripe for a rebound.

Via The Motley Fool

Bull Market and Beyond: 3 Stocks Just Waiting to Soar ↗

April 09, 2024

These stocks, a bargain today, are players to hold on to for the long term.

Via The Motley Fool

Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm

April 02, 2024

--News Direct--

Via News Direct

ARKK’s Tech Bets: Over 500k Roblox Shares Purchased, 1.24M Robinhood Shares Sold ↗

March 29, 2024

Cathie Wood's ARK Innovation ETF had an active trading week, with notable transactions including the purchase of over 500k Roblox shares and the sale of 1.247 million shares of Robinhood Markets.

Via Talk Markets

Topics ETFs

Better Cathie Wood Stock: Moderna vs. Intellia ↗

March 28, 2024

Moderna and Intellia have declined in the double digits over the past year.

Via The Motley Fool

Is Intellia Therapeutics Stock a Buy Now? ↗

March 09, 2024

The company's future will depend on its innovative qualities.

Via The Motley Fool

A Preview Of Intellia Therapeutics's Earnings ↗

February 21, 2024

Via Benzinga

Hot Stocks: The 3 Best Opportunities for Investing in Biotech ↗

March 21, 2024

Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now.

Via InvestorPlace

3 Stocks That Could Be the Next Big Thing in Gene Editing ↗

March 21, 2024

Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.

Via InvestorPlace

Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst ↗

March 06, 2024

2024 could see the start of its first late-stage clinical trials.

Via The Motley Fool

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now ↗

February 29, 2024

The futures for these two beaten-down stocks could be brighter than their recent pasts.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

February 27, 2024

Via The Motley Fool

Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed ↗

February 26, 2024

On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ:

Via Benzinga

Is CRISPR Therapeutics the NVIDIA of gene editing?

February 26, 2024

CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv

Via MarketBeat

Topics Artificial Intelligence

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought ↗

February 20, 2024

These exciting players could deliver explosive growth over time.

Via The Motley Fool

3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential ↗

February 19, 2024

Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.

Via InvestorPlace

Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? ↗

February 17, 2024

Good news may be on the way, but it will be a while before it arrives.

Via The Motley Fool

Earnings Scheduled For February 22, 2024 ↗

February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.

Via Benzinga

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

February 15, 2024

From ReCode Therapeutics

Via Business Wire

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

3 Gene Editing Stocks With Unprecedented Surge Potential ↗

February 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

Via InvestorPlace

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

February 07, 2024

The widely followed growth investor keeps making moves.

Via The Motley Fool

Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock ↗

February 05, 2024

Via Benzinga

A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist ↗

February 05, 2024

These biotech innovators have what it takes to soar.

Via The Motley Fool

Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company ↗

February 01, 2024

Via Benzinga

3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential ↗

January 31, 2024

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.

Via InvestorPlace

History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. ↗

January 30, 2024

Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.

Via The Motley Fool

Topics Stocks

2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street ↗

January 27, 2024

Expectations for these stocks are sky-high, but so are the risks.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com